DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-478/S-012

Abbott Laboratories
200 Abbott Park Road, D-389, J45-2
Abbott Park, IL 60064-6157

Attention: Kathryn B. Patterson
Manager, Regulatory Affairs
Hospital Products Division

Dear Ms. Patterson:

Please refer to your supplemental new drug application dated December 6, 2002, received December 9, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Ultane (sevoflurane) Volatile Liquid for Inhalation.

We acknowledge receipt of your submission dated February 6 and April 23, 2003.

Reference is also made to the June 26, 2003, telephone conversation between you and Lester Schultheis, M.D., of this Division.

This "Changes Being Effected" supplemental new drug application provides for a revised **ADVERSE REACTIONS** and **DOSAGE AND ADMINISTRATION** sections of the package Insert.

We have completed our review of this supplemental new drug application and it is approved effective on the date of this letter.

As agreed to by you, the following subsection of the **DOSAGE AND DMINISTRATION** section will be revised to read:

> *Replacement of Desiccated CO_2 Absorbents:* When a clinician suspects that the CO_2 absorbent may be desiccated, it should be replaced before administration of sevoflurane. The exothermic reaction that occurs with sevoflurane and CO_2 absorbents is increased **when the CO_2 absorbent becomes desiccated, such as after an extended period of dry gas flow through the CO_2 absorbent canisters.** Extremely rare cases of spontaneous fire in the respiratory circuit of the anesthesia machine have been reported during sevoflurane use in conjunction with the use of a desiccated CO_2 absorbent. Rapid changes in the color of some CO_2 absorbents or an unusually delayed rise in the delivered (inspired) gas concentration of sevoflurane compared with the vaporizer setting may indicate excessive heating of the CO_2 absorbent canister and chemical breakdown of sevoflurane.

The changes may be reported in the annual report.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Ms. Lisa Basham-Cruz, Regulatory Project Manager, at (301) 827-7410.

Sincerely,

{See appended electronic signature page}

Bob Rappaport, M.D.
Acting Director
Division of Anesthetic, Critical Care, and
Addiction Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Bob Rappaport

6/27/03 06:28:20 PM